Modus Therapeutics Holding AB announced that the first clinical trial participant has been dosed with sevuparin in the company's clinical Phase 1b LPS provocation study. The randomized, placebo-controlled Phase 1b study will evaluate the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and blood (systemic inflammation). Provocation with LPS is a well-established model used to characterize the early stages of septic inflammation by provoking measurable symptoms. The study will also evaluate the safety profile of sevuparin when used in combination with standard prophylactic, blood-thinning heparin. The study is conducted in collaboration with the Center for Human Drug Research (CHDR) in Leiden, The Netherlands. CHDR is an independent Contract Research Organization (CRO) specializing in advanced early clinical drug research and has strong expertise in advanced inflammation models.